The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study.
Détails
ID Serval
serval:BIB_036B77A3D84B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study.
Périodique
Alzheimer's & dementia
ISSN
1552-5279 (Electronic)
ISSN-L
1552-5260
Statut éditorial
Publié
Date de publication
09/2017
Peer-reviewed
Oui
Volume
13
Numéro
9
Pages
1013-1023
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Publication Status: ppublish
Résumé
Hippocampal volume is a core biomarker of Alzheimer's disease (AD). However, its contribution over the standard diagnostic workup is unclear.
Three hundred fifty-six patients, under clinical evaluation for cognitive impairment, with suspected AD and Mini-Mental State Examination ≥20, were recruited across 17 European memory clinics. After the traditional diagnostic workup, diagnostic confidence of AD pathology (DCAD) was estimated by the physicians in charge. The latter were provided with the results of automated hippocampal volumetry in standardized format and DCAD was reassessed.
An increment of one interquartile range in hippocampal volume was associated with a mean change of DCAD of -8.0% (95% credible interval: [-11.5, -5.0]). Automated hippocampal volumetry showed a statistically significant impact on DCAD beyond the contributions of neuropsychology, <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/single-photon emission computed tomography, and cerebrospinal fluid markers (-8.5, CrI: [-11.5, -5.6]; -14.1, CrI: [-19.3, -8.8]; -10.6, CrI: [-14.6, -6.1], respectively).
There is a measurable effect of hippocampal volume on DCAD even when used on top of the traditional diagnostic workup.
Three hundred fifty-six patients, under clinical evaluation for cognitive impairment, with suspected AD and Mini-Mental State Examination ≥20, were recruited across 17 European memory clinics. After the traditional diagnostic workup, diagnostic confidence of AD pathology (DCAD) was estimated by the physicians in charge. The latter were provided with the results of automated hippocampal volumetry in standardized format and DCAD was reassessed.
An increment of one interquartile range in hippocampal volume was associated with a mean change of DCAD of -8.0% (95% credible interval: [-11.5, -5.0]). Automated hippocampal volumetry showed a statistically significant impact on DCAD beyond the contributions of neuropsychology, <sup>18</sup> F-fluorodeoxyglucose positron emission tomography/single-photon emission computed tomography, and cerebrospinal fluid markers (-8.5, CrI: [-11.5, -5.6]; -14.1, CrI: [-19.3, -8.8]; -10.6, CrI: [-14.6, -6.1], respectively).
There is a measurable effect of hippocampal volume on DCAD even when used on top of the traditional diagnostic workup.
Mots-clé
Alzheimer Disease/cerebrospinal fluid, Alzheimer Disease/complications, Alzheimer Disease/diagnosis, Alzheimer Disease/pathology, Amyloid beta-Peptides/cerebrospinal fluid, Cognition Disorders/diagnostic imaging, Cognition Disorders/etiology, Diagnosis, Computer-Assisted, Diagnosis, Differential, Disease Progression, Europe, Female, Fluorodeoxyglucose F18/metabolism, Hippocampus/pathology, Humans, Male, Neuropsychological Tests, Peptide Fragments/cerebrospinal fluid, Positron-Emission Tomography, Tomography, Emission-Computed, Single-Photon, tau Proteins/cerebrospinal fluid, Alzheimer's disease, Biomarkers, Diagnostic confidence of AD, Hippocampal volume, Medial temporal lobe atrophy
Pubmed
Web of science
Création de la notice
14/03/2017 10:54
Dernière modification de la notice
20/08/2019 12:25
Données d'usage
